l 741626 has been researched along with levodopa in 3 studies
| Studies (l 741626) | Trials (l 741626) | Recent Studies (post-2010) (l 741626) | Studies (levodopa) | Trials (levodopa) | Recent Studies (post-2010) (levodopa) |
|---|---|---|---|---|---|
| 76 | 0 | 33 | 17,774 | 1,900 | 4,946 |
| Protein | Taxonomy | l 741626 (IC50) | levodopa (IC50) |
|---|---|---|---|
| integrase, partial | Human immunodeficiency virus 1 | 0.5939 | |
| lens epithelium-derived growth factor p75 | Homo sapiens (human) | 0.5939 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 2.88 | |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | 3.729 | |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | 2.146 | |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | 2.258 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Brotchie, JM; Millan, MJ; Visanji, NP | 1 |
| Brotchie, JM; Crossman, AR; Hill, MP; McGuire, SG; Millan, MJ; Ravenscroft, P; Rochat, C | 1 |
3 other study(ies) available for l 741626 and levodopa
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Actions at sites other than D(3) receptors mediate the effects of BP897 on l-DOPA-induced hyperactivity in monoamine-depleted rats.
Topics: Adrenergic Uptake Inhibitors; Animals; Behavior, Animal; Biogenic Monoamines; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Hyperkinesis; Indoles; Levodopa; Male; Motor Activity; Piperazines; Piperidines; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D3; Reserpine; Time Factors | 2006 |
Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Disease Models, Animal; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Indoles; Levodopa; Motor Activity; MPTP Poisoning; Oxazines; Piperidines; Receptors, Dopamine D2; Receptors, Dopamine D3; Time Factors | 2006 |